gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Article

Send article

Correlation of PTTG-1 expression with survival in small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC)

Meeting Abstract

Search Medline for

  • corresponding author presenting/speaker Helene Geddert - Institut für Pathologie, Universitätsklinikum Düsseldorf, Deutschland
  • Nina Rehfeld - Klinik für Hämatologie, Onkologie und Klinische Immunologie, Universitätsklinikum Düsseldorf
  • Abedelsalam Atamna - Klinik für Hämatologie, Onkologie und Klinische Immunologie, Universitätsklinikum Düsseldorf
  • Astrid Rohrbeck - Klinik für Hämatologie, Onkologie und Klinische Immunologie, Universitätsklinikum Düsseldorf
  • Helmut E. Gabbert - Institut für Pathologie, Universitätsklinikum Düsseldorf
  • Ralf Kronenwett - Klinik für Hämatologie, Onkologie und Klinische Immunologie, Universitätsklinikum Düsseldorf
  • Rainer Haas - Klinik für Hämatologie, Onkologie und Klinische Immunologie, Universitätsklinikum Düsseldorf
  • Ulrich P. Rohr - Klinik für Hämatologie, Onkologie und Klinische Immunologie, Universitätsklinikum Düsseldorf

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO153

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dkk2006/06dkk263.shtml

Published: March 20, 2006

© 2006 Geddert et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Aims: We examined the expression of the novel oncogene PTTG-1 (pituitary tumor transforming gene) in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) and correlated it to patients’ survival and clinical parameters.

Methods: PTTG-1 expression was examined retrospectively in 136 SCLC and 91 NSCLC by immunohistology. The intensity of PTTG-1 expression was assessed in 3 groups (no, weak and strong positivy) and used for univariate and multivariate analysis.

Results: 36.0% of SCLC showed no PTTG-1 positivity, 44.1% a weak and 19.9% a strong expression. In patients with SCLC, strong PTTG-1 expression was associated with a longer mean survival time compared to patients without or with weak PTTG-1 expression (p=0.029).

Only 2.2% of NSCLC were PTTG-1 negative, 57.1% showed a weak and 40.7% a strong expression. Unlike SCLC, in NSCLC strong PTTG-1 positivity was associated with a shorter mean survival when compared to patients with no or weak PTTG-1 expression (p=0.039). Strong PTTG-1 expression was associated with a more aggressive phenotype showing an advanced pathological stage.

In both, SCLC and NSCLC PTTG-1 expression was a independent predictor for survival in multivariate analysis next to performance status and tumor stage.

Conclusion: PTTG-1 plays an important but discordant role in the pathophysiology of SCLC and NSCLC. As an independent prognostic factor it may serve as a biomarker for better outcome in SCLC patients and a rather unfavorable outcome for patients with NSCLC.